

PRODUCT INFORMATION




CRT5

Item No. 18532

CAS Registry No.: 1034297-58-9
Formal Name: 3-[6-amino-5-(6-ethoxy-2-naphthalenyl)-3-pyridinyl]-N-[2-(dimethylamino)ethyl]-benzamide

Synonym: CRT0066051
MF: C₂₈H₃₀N₄O₂
FW: 454.6
Purity: ≥98%
UV/Vis.: λ_{max}: 234, 333 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CRT5 is supplied as a crystalline solid. A stock solution may be made by dissolving the CRT5 in the solvent of choice, which should be purged with an inert gas. CRT5 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of CRT5 in these solvents is approximately 2.5 and 0.25 mg/ml, respectively.

CRT5 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CRT5 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CRT5 has a solubility of approximately 0.33 in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Protein kinase D (PKD) is a serine/threonine protein kinase that is activated by diacylglycerol, commonly downstream of PKC signaling. The three human PKD isoforms target a variety of proteins to alter cell proliferation, survival, invasion, and protein transport. CRT5 is a pyrazine benzamide that prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively).¹ It has little effect on a panel of additional kinases when given at 1 μM. CRT5 blocks phosphorylation of PKD1 on Ser⁹¹⁶ and PKD2 on Ser⁸⁷⁶, but does not affect PKC-dependent PKD phosphorylation or PKD autophosphorylation.¹ It also decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis.¹

Reference

1. Evans, I.M., Bagherzadeh, A., Charles, M., et al. Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells. *Biochem. J.* **429**(3), 565-572 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM